Breast.Bmk_1.5.0.1.REL_CAPCP
14
6. Fitzgibbons PL, Murphy DA, Hammond EH, Allred DC, Valenstein PN. Recommendations for
validating estrogen and progesterone receptor Immunohistochemistry assays. Arch Pathol Lab
Med. 2010;134(6):930-935.
7. Yildiz-Aktas IZ, Dabbs DJ, Bhargava R. The effect of cold ischemic time on the
immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2
expression in invasive breast carcinoma. Mod Pathol. 2012;25(8):1098-1105.
8. Neumeister VM, Anagnostou V, Siddiqui S, et al. Quantitative assessment of effect of preanalytic
cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst.
2012;104(23)1815-1824.
9. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is
superior to the ligand binding assay for predicting response to adjuvant endocrine therapy in
breast cancer. J Clin Oncol. 1999;17(5):1474-1481.
10. Arber JM, Arber DA, Jenkins KA, Battifora H. Effect of decalcification and fixation in paraffin-
section immunohistochemistry. Appl Immunohistochem. 1996;4:241-248.
11. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed
expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and
tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol.
2007:25(25):3846-3852.
12. McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical
and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab
Med. 1985;109(8):716-721.
13. Shousha S. Oestrogen receptor status of breast carcinoma: Allred/H score conversion table.
Histopathology. 2008;53(3):346-347.
14. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor
immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin
Pathol. 2005:123(1):16-20.
15. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen
and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin
Pathol. 2005:123(1);21-27.
16. Turbin DA, Leung S, Cheang MC, et al. Automated quantitative analysis of estrogen receptor
expression in breast carcinoma does not differ from expert pathologist scoring: a tissue
microarray study of 3,484 cases. Breast Cancer Res Treat. 2008;110(3):417-426.
C. HER2 (ERBB2) Testing
Scientific rationale: A subset of breast carcinomas (approximately 15% to 20%) overexpress human
epidermal growth factor receptor 2 (HER2; HUGO nomenclature ERBB2). Protein overexpression is
usually due to gene amplification. Assays for gene copy number, mRNA quantity, and protein generally
give similar results; gene amplification correlates with protein overexpression in about 95% of cases. In a
small subset of carcinomas (probably <5%), protein overexpression may occur by different mechanisms.
Overexpression is both a prognostic and predictive factor.
Clinical rationale: HER2 status is primarily evaluated to determine patient eligibility for anti-HER2 therapy.
It may identify patients who have a greater benefit from anthracycline-based adjuvant therapy.
Methods: HER2 status can be determined in formalin-fixed paraffin-embedded tissue by assessing
protein expression on the membrane of tumor cells using IHC or by assessing the number of HER2 gene
copies using in situ hybridization (ISH). When both IHC and ISH are performed on the same tumor, the